Details

Autor(en) / Beteiligte

• Fellström, Bengt C
• Jardine, Alan G
• Schmieder, Roland E
• Holdaas, Hallvard
• Bannister, Kym
• Beutler, Jaap
• Chae, Dong-Wan
• Chevaile, Alejandro
• Cobbe, Stuart M
• Grönhagen-Riska, Carola
• De Lima, José J
• Lins, Robert
• Mayer, Gert
• McMahon, Alan W
• Parving, Hans-Henrik
• Remuzzi, Giuseppe
• Samuelsson, Ola
• Sonkodi, Sandor
• Sci, D
• Süleymanlar, Gultekin
• Tsakiris, Dimitrios
• Tesar, Vladimir
• Todorov, Vasil
• Wiecek, Andrzej
• Wüthrich, Rudolf P
• Gottlow, Mattis
• Johnsson, Eva
• Zannad, Faiez

Titel

Rosuvastatin and Cardiovascular Events in Patients Undergoing Hemodialysis

Ist Teil von

• The New England journal of medicine, 2009-04, Vol.360 (14), p.1395-1407

Ort / Verlag

Waltham, MA: Massachusetts Medical Society

Erscheinungsjahr

2009

Quelle

MEDLINE

Beschreibungen/Notizen

• In a multicenter, randomized trial, 2776 patients undergoing maintenance hemodialysis who were not currently taking a statin were randomly assigned to rosuvastatin or placebo. At a median of 3.8 years of follow-up, rates of the composite primary end point of death from cardiovascular causes, myocardial infarction, or stroke did not differ significantly between the two study groups. Patients undergoing maintenance hemodialysis were randomly assigned to rosuvastatin or placebo. At a median of 3.8 years of follow-up, rates of the composite primary end point of death from cardiovascular causes, myocardial infarction, or stroke did not differ significantly between the two study groups. Patients undergoing maintenance hemodialysis have a greatly increased risk of premature cardiovascular disease. 1 , 2 However, the pattern of cardiovascular disease in such patients differs from that in the general population, and although the risk of myocardial infarction is increased, other cardiovascular events, such as sudden cardiac death and heart failure, predominate. 1 – 3 Moreover, the relationship between cardiovascular disease and conventional risk factors is inconsistent, inverse, or U-shaped. 1 , 2 , 4 Since low-density lipoprotein (LDL) cholesterol levels may be low or normal in patients with advanced renal disease, there is particular uncertainty regarding the use of lipid-lowering therapy. 1 , 2 , 4 , 5 Statin . . .